Plus   Neg

Hexcel To Buy ARC Technologies For $160 Mln - Quick Facts

Hexcel Corp. (HXL) said Friday that it has agreed to acquire ARC Technologies, Inc., a supplier of custom RF / EMI and microwave absorbing composite materials for military, aerospace and industrial applications for an agreed-upon purchase price of $160 million.

Hexcel noted that the acquisition will strengthen its existing advanced materials portfolio in structural composites and thermoplastics as well as provide new opportunities for growth and market penetration.

Founded in 1988, ARC Technologies is a privately-owned manufacturer with about 170 employees working at two locations in Amesbury, Massachusetts.

The company has a wide range of capabilities for producing RF / EMI and microwave absorbing materials and specializes in combining absorptive metallic filler compounds - including carbon, iron and nickel-coated graphite - with a proprietary blend of polymer resins to generate various matrix materials including structural composites and thermoplastics.

Hexcel noted that ARC Technologies is expected to generate about $50 million in revenue in 2018.

The transaction, anticipated to be accretive to Hexcel's earnings in 2019, is expected to close early in 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT